GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Scancell Holdings PLC (AQSE:SCLP.GB) » Definitions » Equity-to-Asset

Scancell Holdings (AQSE:SCLP.GB) Equity-to-Asset : -0.38 (As of Oct. 2023)


View and export this data going back to 2013. Start your Free Trial

What is Scancell Holdings Equity-to-Asset?

Equity to Asset ratio is calculated as total stockholders equity divided by total asset. Scancell Holdings's Total Stockholders Equity for the quarter that ended in Oct. 2023 was £-8.36 Mil. Scancell Holdings's Total Assets for the quarter that ended in Oct. 2023 was £22.25 Mil.

The historical rank and industry rank for Scancell Holdings's Equity-to-Asset or its related term are showing as below:

AQSE:SCLP.GB' s Equity-to-Asset Range Over the Past 10 Years
Min: -0.38   Med: 0.92   Max: 0.96
Current: -0.38

During the past 13 years, the highest Equity to Asset Ratio of Scancell Holdings was 0.96. The lowest was -0.38. And the median was 0.92.

AQSE:SCLP.GB's Equity-to-Asset is ranked worse than
88.43% of 1565 companies
in the Biotechnology industry
Industry Median: 0.67 vs AQSE:SCLP.GB: -0.38

Scancell Holdings Equity-to-Asset Historical Data

The historical data trend for Scancell Holdings's Equity-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Scancell Holdings Equity-to-Asset Chart

Scancell Holdings Annual Data
Trend Apr14 Apr15 Apr16 Apr17 Apr18 Apr19 Apr20 Apr21 Apr22 Apr23
Equity-to-Asset
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.89 0.87 0.18 0.13 -0.21

Scancell Holdings Semi-Annual Data
Apr14 Oct14 Apr15 Oct15 Apr16 Oct16 Apr17 Oct17 Apr18 Oct18 Apr19 Oct19 Apr20 Oct20 Apr21 Oct21 Apr22 Oct22 Apr23 Oct23
Equity-to-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.51 0.13 0.40 -0.21 -0.38

Competitive Comparison of Scancell Holdings's Equity-to-Asset

For the Biotechnology subindustry, Scancell Holdings's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Scancell Holdings's Equity-to-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Scancell Holdings's Equity-to-Asset distribution charts can be found below:

* The bar in red indicates where Scancell Holdings's Equity-to-Asset falls into.



Scancell Holdings Equity-to-Asset Calculation

Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.

Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.

Scancell Holdings's Equity to Asset Ratio for the fiscal year that ended in Apr. 2023 is calculated as

Equity to Asset (A: Apr. 2023 )=Total Stockholders Equity/Total Assets
=-6.233/30.27
=-0.21

Scancell Holdings's Equity to Asset Ratio for the quarter that ended in Oct. 2023 is calculated as

Equity to Asset (Q: Oct. 2023 )=Total Stockholders Equity/Total Assets
=-8.363/22.252
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Scancell Holdings  (AQSE:SCLP.GB) Equity-to-Asset Explanation

Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.

For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.


Scancell Holdings Equity-to-Asset Related Terms

Thank you for viewing the detailed overview of Scancell Holdings's Equity-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


Scancell Holdings (AQSE:SCLP.GB) Business Description

Traded in Other Exchanges
Address
Sanders Road, Unit 202, Bellhouse Building, Oxford Science Park, Oxford, GBR, OX4 4GD
Scancell Holdings PLC is engaged in the discovery and development of novel vaccines for the treatment of cancer. The company is exploiting the unrivalled potential of the immune system to seek out and destroy cancer using two proprietary immuno-oncology platforms: ImmunoBody and Moditope. Its potent innovative DNA-based ImmunoBody therapies generate ultra-high avidity T cell responses that target and eliminate cancerous tumors. Its Moditope platform technology overcomes the immune suppression induced by tumors themselves, allowing activated T cells to seek out and kill tumor cells that would otherwise be hidden from the immune system.

Scancell Holdings (AQSE:SCLP.GB) Headlines

No Headlines